KOSS vs CLOV

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 01, 2026

KOSS

27.2
AI Score
VS
CLOV Wins

CLOV

44.3
AI Score

Investment Advisor Scores

KOSS

27score
Recommendation
AVOID NEW MONEY

CLOV

44score
Recommendation
HOLD

AI Analyst Insights

Detailed Metrics Comparison

Metric KOSS CLOV Winner
Forward P/E 526.3158 37.7358 CLOV
PEG Ratio 0 0 Tie
Revenue Growth 5.8% 55.6% CLOV
Earnings Growth 37.1% 0.0% KOSS
Tradestie Score 27.2/100 44.3/100 CLOV
Profit Margin -3.0% -0.7% CLOV
Beta 1.00 1.00 Tie
AI Recommendation AVOID NEW MONEY HOLD CLOV

Relative Price Performance (Last 90 Days)

KOSS 1M: +10.9% · 3M: -5.1% CLOV 1M: +2.1% · 3M: -13.2%

Current Technical Phase

KOSS

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 56

RSI (14): 55.9 · Price: $3.88

CLOV

Distribution
Trim / tighten stop

Price near a flattening SMA50 (slope -3.2%) with fading momentum, RSI 48

RSI (14): 48.0 · Price: $4.39

Fundamentals Snapshot

Metric KOSS CLOV
Market Cap — —
Forward P/E 526.3 28.2
Trailing P/E — —
Revenue (TTM) — —
Revenue Growth 0.1% 0.6%
Gross Margin 0.4% 0.2%
Operating Margin -0.3% 0.0%
EPS -0.04 -0.05
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, CLOV is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.